Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06767514 · ClinicalTrials.gov registry record · Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Summit Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 780
- Enrollment target
- 20
- Study locations
NCT06767514 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Summit Therapeutics. The registered enrollment target is 780 participants, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT06767514, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Summit Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 780 participants
- Enrollment target
- 20
- Study locations
Study Summary
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Conditions Studied
Interventions
- BIOLOGICAL Ivonescimab Injection
- BIOLOGICAL Pembrolizumab Injection
Study Locations (20)
California
- Clinical Study Site - Cerritos
- Clinical Study Site - Glendale
- Clinical Study Site - Irvine
- Clinical Study Site - Los Angeles
- Clinical Study Site - Mountain View
- Clinical Study Site - Murrieta
- Clinical Study Site - Newport Beach
- Clinical Study Site - Roseville
- Clinical Study Site - Sacramento
- Clinical Study Site - San Diego
- Clinical Study Site - San Francisco
- Clinical Study Site - Santa Ana
- Clinical Study Site - Whittier
Colorado
- Clinical Study Site - Aurora
- Clinical Study Site - Grand Junction
- Clinical Study Site - Greeley
- Clinical Study Site - Lone Tree
Arizona
- Clinical Study Site - Chandler
- Clinical Study Site - Phoenix
Arkansas
- Clinical Study Site - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 780 participants |
| Start Date | 2025-02-27 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06767514
The ClinicalTrials.gov registry entry for NCT06767514 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 780 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 657-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (19% higher). The listed sponsor is Summit Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ivonescimab Injection is the first listed.
NCT06767514 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT06767514 about?
NCT06767514 is a clinical study titled "Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1". Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
What is the current status of trial NCT06767514?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 780 participants. The study started on 2025-02-27. Estimated completion is 2029-06.
What conditions does trial NCT06767514 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06767514?
The interventions under investigation include: Ivonescimab Injection (BIOLOGICAL), Pembrolizumab Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT06767514?
This trial is sponsored by Summit Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06767514 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.